RxDoctor Payments Data

Paul Richardson, MD

Urology · Waterloo, IANPI 1124018999

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (54.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Neotract Inc. at 36.1% of the total.

$4,218in general payments, 2019–2025

Across 86 payments — averaging $49.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$2K
  • Procept Biorobotics Corporation$1K
  • Astellas Pharma US Inc$535
  • AbbVie$203
  • Pfizer$193
  • Johnson & Johnson$181
  • plus $506 from 11 others

What the payments were for

  • Travel & lodging$2,30055%
  • Food & beverage$1,61838%
  • Education$3007%

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,218 in reported general payments places this provider in the 70th percentile of 114 urology providers in Iowa.

See all urology providers in Iowa

Medicare billing

Part B allowed, 2024
$60,367
Medicare patients
406
Services billed
661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron206$146,849
GemtesaVibegron28$20,946
Tamsulosin Hcl783$16,649
Oxybutynin Chloride ErOxybutynin Chloride360$8,678
Dutasteride225$7,893
Oxybutynin Chloride94$4,183
Potassium Citrate ErPotassium Citrate44$3,862
Solifenacin Succinate99$3,754
Finasteride276$3,619
Silodosin29$1,939
Terazosin Hcl100$1,429
Testosterone Cypionate60$1,139
Tolterodine Tartrate ErTolterodine Tartrate11$875
Bicalutamide21$776
Doxazosin Mesylate39$751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$535$146,849206 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 114 urology providers in Iowa.

Other urology in Waterloo

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →